Immunoglobulin M (IgM) is a type of antibody produced by the immune system. It’s one of the first antibodies to be produced in response to an infection, particularly during the early stages of an immune response. IgM is mainly found in the bloodstream and lymphatic system. Testing the levels of IgM in the serum can provide valuable information about the body’s immune response to various infections or diseases. Elevated levels of IgM may indicate an acute or recent infection, while low levels could suggest immune deficiency or a chronic infection.

Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are both genetic disorders caused by mutations in the dystrophin gene, located on the X chromosome. These mutations result in the absence or abnormality of the protein dystrophin, which is essential for maintaining the structural integrity of muscle cells.

DMD is typically more severe and manifests earlier in life, usually in early childhood. Symptoms include progressive muscle weakness, difficulty walking, frequent falls, and eventually, wheelchair dependence. BMD, on the other hand, tends to have a later onset and progresses more slowly. Individuals with BMD may have milder symptoms and a longer life expectancy compared to those with DMD.

The specific type of mutation in the dystrophin gene can vary among individuals with DMD or BMD. These mutations can include deletions, duplications, insertions, or point mutations within the gene. Genetic testing, such as DNA sequencing or multiplex ligation-dependent probe amplification (MLPA), is often used to identify these mutations and confirm a diagnosis of DMD or BMD. Early diagnosis through genetic testing is crucial for appropriate medical management and treatment planning for individuals with these conditions.